Skip to content
drillr.ai
Sign up

300765.SZ

CSPC Innovation Pharmaceutical Co., Ltd.

SZSE · Consumer Defensive · C 制造业 · CN

CNY 37.56
−2.59%
Ask drillr

  • Oct 30, 2026, 08:17 UTC

    Jushi Biopharmaceutical began a Phase I/II trial evaluating SYS6043, alone and in combination with bevacizumab and chemotherapy, in participants with advanced solid tumors; recruitment and screening are underway.

    Source:

  • Oct 22, 2026, 08:32 UTC

    Jushi Biologics, a subsidiary of CSPC Innovation, initiated a Phase III clinical trial of SYS6043 for first-line treatment of unresectable recurrent or metastatic triple-negative breast cancer.

    Source:

  • Oct 15, 2026, 08:34 UTC

    China’s National Medical Products Administration approved a clinical trial for SYS6062, developed by CSPC Pharmaceutical Group Ltd., for advanced solid tumors.

    Source:

  • Oct 15, 2026, 08:33 UTC

    China's National Medical Products Administration approved a clinical trial of SYS6088 injection for advanced or metastatic solid tumors in China.

    Source:

  • Oct 4, 2026, 01:01 UTC

    CSPC Innovation said on its investor interaction platform that commercialization work for its ustekinumab injection is progressing in an orderly manner.

    Source:

  • Sep 30, 2026, 03:44 UTC

    Chinese innovative drug stocks rallied in both Hong Kong and mainland China on Wednesday, with CanSino Biologics up 19% and Laekna up 18.6% in Hong Kong, and Sinovent up 14% and CSPC Innovation up 8.5% on the A-share market.

    Source:

  • Sep 14, 2026, 08:19 UTC

    CSPC Innovation's controlling subsidiary Giant Stone Biotech presented Phase I/II clinical data for SYS6010 combined with enlonstobart in advanced non-small cell lung cancer at the 2026 World Conference on Lung Cancer.

    Source:

  • Aug 27, 2026, 09:14 UTC

    Shijiazhuang Pharma Innovation's controlled subsidiary Shijiazhuang Pharmaceutical Group Jushi Biopharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials for its SYH2092 injection in China.

    Source:

  • Aug 21, 2026, 02:03 UTC

    As of August 20, 2026, the total margin trading balance on China's A-share market decreased by 1.248 billion yuan to 2.666356 trillion yuan, with net financing purchases led by Zhongji Innolight at 530 million yuan.

    Source:

  • Aug 17, 2026, 14:09 UTC

    CSPC Pharmaceutical Group's subsidiary CSPC Innovation Pharmaceutical reported a net profit of 1.261 billion yuan for the first half of 2026, turning around from a loss of 2.75 million yuan a year earlier, with revenue up 208.7% year-on-year to 3.24 billion yuan.

    Source:

  • Aug 3, 2026, 08:02 UTC

    Jushi Biologics, a controlled subsidiary of CSPC Innovation, initiated the Ib/II phase clinical trial (SYS6090-008) of SYS6090 injection in combination therapy for advanced or metastatic colorectal cancer; the product is a Class 1 therapeutic biologic recombinant fully human anti-PD-1 fusion IL-15 protein.

    Source:

  • Jul 31, 2026, 08:16 UTC

    Shiyao Innovation announced that its controlling subsidiary Jushi Biologics initiated a Phase II clinical trial of SYS6041 in combination therapy for recurrent ovarian cancer, which was approved by the National Medical Products Administration in June 2026.

    Source:

  • Jul 27, 2026, 11:51 UTC

    MegaStone Biologics received a full upfront payment of $420 million from AstraZeneca on May 29, 2026, and recognized part of it as revenue.

    Source: